NCT01859962
- Conditions
- Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
- Locations
-
- Quest Clinical Research San Francisco, California, United States
Clinical trial condition
Flaviviridae Infections
Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.
2,144 public trials
77 recruiting studies
Flaviviridae Infections trial results
NCT01859884
- Conditions
- Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Chronic Disease, +35 more
- Locations
-
- University of Alabama at Birmingham Birmingham, Alabama, United States
- Northwestern Memorial Hospital Chicago, Illinois, United States
NCT01830127
- Conditions
- Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
- Locations
-
- 1241.30.10003 Boehringer Ingelheim Investigational Site La Mesa, California, United States
- 1241.30.10007 Boehringer Ingelheim Investigational Site San Diego, California, United States
- 1241.30.10001 Boehringer Ingelheim Investigational Site DeLand, Florida, United States
- 1241.30.10012 Boehringer Ingelheim Investigational Site West Palm Beach, Florida, United States
NCT01517529
- Conditions
- Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
- Locations
-
- University of Cincinnati Cincinnati, Ohio, United States
NCT01361776
- Conditions
- Arbovirus Infections, Brain Diseases, Central Nervous System Diseases, +17 more
- Locations
-
- Dept infectious diseases Helsingfors, Finland
- Dept infectious diseases Eskilstuna, Sweden
- Dept infectious diseases Karlstad, Sweden
- Department of infectious diseases Örebro, Sweden
Completed
A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects
NCT00546715
- Conditions
- Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
- Locations
-
- Advanced Clinical Research Institute Anaheim, California, United States
- Orlando Clinical Research Center Orlando, Florida, United States
- Parexel International Corporation Baltimore, Maryland, United States
- Mayo Clinic Rochester, Minnesota, United States
Completed
Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)
NCT00774397
- Conditions
- Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
- Locations
-
- 1220.5.0001 Boehringer Ingelheim Investigational Site San Francisco, California, United States
- 1220.5.0008 Boehringer Ingelheim Investigational Site San Francisco, California, United States
- 1220.5.0005 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States
- 1220.5.0006 Boehringer Ingelheim Investigational Site Lutherville, Maryland, United States
NCT01830205
- Conditions
- Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
- Locations
-
- Orlando Clinical Research Center Orlando, Florida, United States
- Davita Clinical Research Minneapolis, Minnesota, United States
NCT01908660
- Conditions
- Acquired Immunodeficiency Syndrome, Blood-Borne Infections, Chronic Disease, +32 more
- Locations
-
- Hospital Universitario de Valme Seville, Spain
NCT01726400
- Conditions
- Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
- Locations
-
- Fremantle Hospital Fremantle, Western Australia, Australia